Fate Therapeutics Inc(FATE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

FATE Fate Therapeutics Inc

未开盘 08-28 16:00:00 EDT

2.43

-0.11

-4.33%

盘后2.43

+0.00-0.02%

19:48 EDT

最高2.53	最低2.41	成交量71.49万
今开2.51	昨收2.54	日振幅4.72%
总市值2.92亿	流通市值2.55亿	总股本1.20亿
成交额175.35万	换手率0.68%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics Inc","latestPrice":2.43,"timestamp":1787947200000,"preClose":2.54,"halted":0,"volume":714904,"hourTrading":{"tag":"盘后","latestPrice":2.4295,"preClose":2.43,"latestTime":"19:48 EDT","volume":6269,"amount":15194.6775,"timestamp":1787960932256,"change":-0.0005,"changeRate":-0.000206,"amplitude":0.004115},"delay":0,"changeRate":-0.04330708661417318,"floatShares":104935918,"shares":120000000,"eps":-1.052849,"marketStatus":"未开盘","change":-0.11,"latestTime":"08-28 16:00:00 EDT","open":2.51,"high":2.53,"low":2.41,"amount":1753471.2062864,"amplitude":0.047244,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.052849,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":2.54,"preHourTrading":{"tag":"盘前","latestPrice":2.54,"preClose":2.54,"latestTime":"09:26 EDT","volume":286,"amount":723.1900390000001,"timestamp":1787923567244,"change":0,"changeRate":0,"amplitude":0.019685},"postHourTrading":{"tag":"盘后","latestPrice":2.4295,"preClose":2.43,"latestTime":"19:48 EDT","volume":6269,"amount":15194.6775,"timestamp":1787960932256,"change":-0.0005,"changeRate":-0.000206,"amplitude":0.004115},"volumeRatio":0.4427865281420568,"impliedVol":0.7252,"impliedVolPercentile":0.2151},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"1144454859","title":"Fate Therapeutics：患者将接受单次9亿细胞剂量的FT819；主要终点在第26周","url":"https://stock-news.laohu8.com/highlight/detail?id=1144454859","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144454859?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:01","pubTimestamp":1786705274,"startTime":"0","endTime":"0","summary":"Fate Therapeutics公司宣布，患者将接受单次9亿细胞剂量的FT819治疗。该研究的主要终点将在第26周进行评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178447377","title":"Fate Therapeutics 启动FT819用于狼疮性肾炎的潜在注册性Reclaim-Ln临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1178447377","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178447377?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:01","pubTimestamp":1786705269,"startTime":"0","endTime":"0","summary":"Fate Therapeutics 正式宣布，已启动一项具有潜在注册价值的Reclaim-Ln临床试验，旨在评估其候选疗法FT819在狼疮性肾炎治疗中的效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169751450","title":"Fate Therapeutics获FDA批准其FT839候选产品新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1169751450","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169751450?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:32","pubTimestamp":1783600338,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc宣布，其候选产品FT839的新药临床试验申请已获得美国食品药品监督管理局的批准。这一进展标志着该产品向临床开发阶段迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183313373","title":"Fate Therapeutics - FT839试验初期将瞄准类风湿关节炎、血管炎、肌炎、狼疮及系统性硬化症","url":"https://stock-news.laohu8.com/highlight/detail?id=1183313373","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183313373?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:31","pubTimestamp":1783600289,"startTime":"0","endTime":"0","summary":"Fate Therapeutics宣布，其FT839试验的初步目标将集中于类风湿关节炎、血管炎、肌炎、狼疮以及系统性硬化症等适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167889454","title":"Fate Therapeutics宣布在2026年ASCO和EULAR年会上展示针对癌症与自身免疫性疾病的现货型CAR T细胞疗法管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1167889454","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167889454?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:30","pubTimestamp":1779366627,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc宣布，将在2026年美国临床肿瘤学会（ASCO）和欧洲抗风湿病联盟（EULAR）年度会议上，展示其针对癌症及自身免疫性疾病的现货型CAR T细胞疗法研发管线。这一系列报告将重点介绍公司在开发即用型细胞免疫疗法方面的最新进展与成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126566418","title":"Fate Therapeutics获选加入美国FDA化学、制造与控制开发与准备试点计划，助力FT819生产准备","url":"https://stock-news.laohu8.com/highlight/detail?id=1126566418","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126566418?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:31","pubTimestamp":1777984278,"startTime":"0","endTime":"0","summary":"Fate Therapeutics公司近日成功入选美国食品药品监督管理局（FDA）的化学、制造与控制开发与准备试点计划。该计划旨在支持其创新疗法FT819的生产准备工作，标志着公司在细胞疗法制造领域的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197290420","title":"Fate Therapeutics将在2026年美国基因与细胞治疗学会年会展示三项研究成果，重点推介针对癌症及自身免疫性疾病的现货型CAR-T细胞疗法管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1197290420","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197290420?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:01","pubTimestamp":1777899703,"startTime":"0","endTime":"0","summary":"Fate Therapeutics公司近日宣布，其研发团队将于2026年美国基因与细胞治疗学会（ASGCT）年会上进行三项重要研究成果展示。这些报告将集中呈现该公司在现货型CAR-T细胞疗法领域的最新突破，相关疗法主要针对癌症与自身免疫性疾病两大治疗方向。\n此次学术会议将成为Fate Therapeutics展示其创新疗法管线的重要平台。通过三项专题报告，研发人员将详细阐述其在同种异体CAR-T细胞治疗技术方面的进展，包括治疗机制、临床前数据及未来临床应用前景。这些研究成果有望为癌症和自身免疫性疾病患者提供更具可及性的现成细胞治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190381786","title":"Fate Therapeutics Inc：预计运营资金可支撑至2027年底，现金及投资总额达2.05亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190381786","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190381786?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:12","pubTimestamp":1772115126,"startTime":"0","endTime":"0","summary":"生物技术公司Fate Therapeutics Inc宣布，其现有资金储备足以维持公司运营至2027年底。公司目前持有现金、现金等价物及各类投资合计2.05亿美元，为后续细胞疗法研发提供了坚实财务基础。这一资金规划将支持公司推进包括CAR-NK和iPSC衍生细胞疗法在内的多项临床前及临床阶段项目，同时保障企业在新药研发关键阶段的持续投入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518149227","title":"Fate Therapeutics, Inc.盘中异动 早盘快速下挫5.66%报0.953美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518149227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518149227?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:50","pubTimestamp":1741614611,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时50分，Fate Therapeutics, Inc.股票出现异动，股价大幅下挫5.66%。截至发稿，该股报0.953美元/股，成交量11.0385万股，换手率0.10%，振幅2.97%。Fate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2739.31%、617.86%、95.77%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Fate Therapeutics, Inc.公司简介：Fate Therapeutics Inc是一家总部位于美国的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021501196403af3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021501196403af3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518788289","title":"Fate Therapeutics, Inc.2024财年实现净利润-1.86亿美元，同比减少15.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518788289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518788289?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:00","pubTimestamp":1741536051,"startTime":"0","endTime":"0","summary":"3月10日，Fate Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.86亿美元，同比减少15.53%；其中营业收入为13.63百万美元，同比减少78.55%，每股基本收益为-1.64美元。机构评级：截至2025年3月10日，当前有11家机构对Fate Therapeutics, Inc.目标价做出预测，其中目标均价为6.64美元，其中最低目标价为3.00美元，最高目标价为12.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000116abf1752b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000116abf1752b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517758162","title":"Stifel：维持Fate Therapeutics(FATE.US)评级，由持有调整至持有评级, 目标价由5.00美元调整至3.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517758162","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517758162?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:05","pubTimestamp":1741277144,"startTime":"0","endTime":"0","summary":"Stifel：维持Fate Therapeutics(FATE.US)评级，由持有调整至持有评级, 目标价由5.00美元调整至3.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/07000548577051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["FATE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517734989","title":"Fate Therapeutics(FATE.US)：2024年Q4财报实现营收186万美元，前值为167.6万美元，预期值为157万美元；每股收益为-0.44美元，前值为-0.45美元，预期值为-0.43美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517734989","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517734989?lang=zh_cn&edition=full","pubTime":"2025-03-06 07:18","pubTimestamp":1741216725,"startTime":"0","endTime":"0","summary":"Fate Therapeutics(FATE.US)：2024年Q4财报实现营收186万美元，前值为167.6万美元，预期值为157万美元；每股收益为-0.44美元，前值为-0.45美元，预期值为-0.43美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06071848551671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129075237","title":"Fate Therapeutics 2024年第四季度GAAP每股收益$(0.44) 不及预期$(0.43)，销售额$1.860 不及预期$1.416百万","url":"https://stock-news.laohu8.com/highlight/detail?id=1129075237","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129075237?lang=zh_cn&edition=full","pubTime":"2025-03-06 05:11","pubTimestamp":1741209061,"startTime":"0","endTime":"0","summary":"Fate Therapeutics报告2024年第四季度每股亏损$，未能达到分析师一致预期的$，低于预期2.33%。公司报告季度销售额为$1.860，未达到分析师一致预期的$1.416百万，低于预期100%。与去年同期销售额$1.676百万相比，下降了100%。以上内容来自Benzinga Earnings专栏，原文如下：Fate $Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 2.33 percent. This is a 2.22 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $1.860 which missed the analyst consensus estimate of $1.416 million by 100.00","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Fate Therapeutics 2024年第四季度GAAP每股收益$(0.44) 不及预期$(0.43)，销售额$1.860 不及预期$1.416百万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517794153","title":"Fate Therapeutics, Inc.盘中异动 早盘大幅下挫5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517794153","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517794153?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:24","pubTimestamp":1741191843,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时24分，Fate Therapeutics, Inc.股票出现波动，股价大幅下跌5.05%。Fate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.12%。其相关个股中，Chimerix, Inc.、Nutriband Inc C/Wts 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为904.73%、293.48%、278.75%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为82.59%、54.27%、41.26%。Fate Therapeutics, Inc.公司简介：Fate Therapeutics Inc是一家总部位于美国的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306002403963af686&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306002403963af686&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FATE","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516373366","title":"Fate Therapeutics, Inc.盘中异动 急速下挫5.36%报1.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516373366","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516373366?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:02","pubTimestamp":1741014147,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时02分，Fate Therapeutics, Inc.股票出现异动，股价快速下跌5.36%。Fate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为975.81%、123.66%、98.58%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、48.34%。Fate Therapeutics, Inc.公司简介：Fate Therapeutics Inc是一家总部位于美国的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230227a25d4965&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230227a25d4965&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FATE","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320226","title":"Fate Therapeutics, Inc.盘中异动 早盘股价大跌5.50%报1.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320226","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514320226?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753086,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Fate Therapeutics, Inc.股票出现波动，股价快速下跌5.50%。截至发稿，该股报1.03美元/股，成交量5.7451万股，换手率0.05%，振幅3.67%。Fate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Fate Therapeutics, Inc.公司简介：Fate Therapeutics Inc是一家总部位于美国的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822312698967993&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822312698967993&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FATE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514317223","title":"Fate Therapeutics, Inc.盘中异动 股价大跌5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514317223","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514317223?lang=zh_cn&edition=full","pubTime":"2025-02-28 03:34","pubTimestamp":1740684867,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日03时34分，Fate Therapeutics, Inc.股票出现波动，股价快速跳水5.17%。Fate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.11%。其相关个股中，Pepgen Inc.、Alpha Tau Medical Ltd C/Wts 、Ibio, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1904.24%、330.55%、183.83%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Fate Therapeutics, Inc.公司简介：Fate Therapeutics Inc是一家总部位于美国的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022803342898954802&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022803342898954802&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FATE","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514869287","title":"Fate Therapeutics, Inc.盘中异动 下午盘大幅跳水5.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514869287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514869287?lang=zh_cn&edition=full","pubTime":"2025-02-27 02:56","pubTimestamp":1740596203,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日02时56分，Fate Therapeutics, Inc.股票出现波动，股价快速跳水5.69%。Fate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Nkgen Biotech Inc C/Wts 31/05/2028涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6511.90%、287.16%、255.94%，振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Organovo Holdings, Inc.，振幅分别为194.07%、78.53%、52.76%。Fate Therapeutics, Inc.公司简介：Fate Therapeutics Inc是一家总部位于美国的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022702564396317f81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022702564396317f81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FATE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513722757","title":"Fate Therapeutics, Inc.盘中异动 股价大跌5.56%报1.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722757","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513722757?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:42","pubTimestamp":1740408139,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时42分，Fate Therapeutics, Inc.股票出现异动，股价大幅跳水5.56%。截至发稿，该股报1.34美元/股，成交量6.8867万股，换手率0.06%，振幅4.23%。Fate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Fate Therapeutics, Inc.公司简介：Fate Therapeutics Inc是一家总部位于美国的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242242199890f89c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242242199890f89c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513299115","title":"Fate Therapeutics, Inc.盘中异动 早盘急速下挫5.17%报1.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513299115","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513299115?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:07","pubTimestamp":1740150451,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时07分，Fate Therapeutics, Inc.股票出现波动，股价大幅下跌5.17%。Fate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为119.86%、95.38%、72.08%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Omega Therapeutics, Inc.，振幅分别为67.41%、57.50%、35.45%。Fate Therapeutics, Inc.公司简介：Fate Therapeutics Inc是一家总部位于美国的临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230731962b840d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230731962b840d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0429},{"period":"1month","weight":0.0297},{"period":"3month","weight":-0.1444},{"period":"6month","weight":0.6419},{"period":"1year","weight":1.25},{"period":"ytd","weight":1.473}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Fate Therapeutics, Inc.于2007年4月27日在特拉华州注册成立，总部位于加利福尼亚州圣地亚哥。作为一家临床阶段的生物制药公司，该公司专注于开发现成的、多重工程、诱导多能干细胞（iPSC）衍生的细胞免疫疗法，旨在用于患者治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.461538,"avgChangeRate":0.079338},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.000833},{"month":7,"riseRate":0.384615,"avgChangeRate":0.039214},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.023338},{"month":9,"riseRate":0.416667,"avgChangeRate":0.00072},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics Inc","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics Inc(FATE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Fate Therapeutics Inc(FATE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Fate Therapeutics Inc,FATE,Fate Therapeutics Inc股票,Fate Therapeutics Inc股票老虎,Fate Therapeutics Inc股票老虎国际,Fate Therapeutics Inc行情,Fate Therapeutics Inc股票行情,Fate Therapeutics Inc股价,Fate Therapeutics Inc股市,Fate Therapeutics Inc股票价格,Fate Therapeutics Inc股票交易,Fate Therapeutics Inc股票购买,Fate Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics Inc(FATE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Fate Therapeutics Inc(FATE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}